1/4 #ESMO26 GU preview: a few studies I’ll be watching next week, starting with #ProstateCancer. 👇 🔵 #DASLHiCaP — LBA4 - Darolutamide + ADT + definitive/salvage RT in very-high-risk localized prostate cancer. - Can this provide another intensification option with RT? Particularly interested in the salvage population, absolute benefit, and tolerability. 🔵 #PROTEUS substudy — LBA53 - Perioperative apalutamide + ADT + prostatectomy vs surgery alone. - A better comparison IMO beyond the parent trial’s ADT control. Looking for durable outcomes and whether systemic treatment reduces subsequent salvage therapy. Also watching #CAPItello281 updated OS and mature #PEACE1 survival. @myESMO @OncoAlert @oncodaily @OncoDailyGU @urotoday @GUOncologyNow